159 related articles for article (PubMed ID: 38359680)
1. Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?
Record SM; Thomas SM; Tian WM; van den Bruele AB; Chiba A; DiLalla G; DiNome ML; Kimmick G; Rosenberger LH; Woriax HE; Hwang ES; Plichta JK
J Surg Res; 2024 Apr; 296():654-664. PubMed ID: 38359680
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?
Lee E; Tweed C; Mylander C; Martino L; Rosman M; Huerta N; Waite K; Tafra L; Jackson RS
Clin Breast Cancer; 2021 Dec; 21(6):e731-e737. PubMed ID: 34006481
[TBL] [Abstract][Full Text] [Related]
3. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
[TBL] [Abstract][Full Text] [Related]
4. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer.
Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF
JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER.
Davey MG; Kerin EP; McLaughlin RP; Barry MK; Malone CM; Elwahab SA; Lowery AJ; Kerin MJ
Clin Breast Cancer; 2023 Jul; 23(5):500-507. PubMed ID: 37076364
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
7. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
Knape N; Park JH; Agala CB; Spanheimer P; Morrow M; Downs-Canner S; Baldwin XL
Ann Surg Oncol; 2023 Feb; 30(2):1042-1050. PubMed ID: 36217063
[TBL] [Abstract][Full Text] [Related]
8. Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.
McKevitt E; Cheifetz R; DeVries K; Laws A; Warburton R; Gondara L; Lohrisch C; Nichol A
Ann Surg Oncol; 2021 Oct; 28(11):5950-5957. PubMed ID: 33817760
[TBL] [Abstract][Full Text] [Related]
9. Survival After Sentinel Lymph Node Biopsy Compared with Axillary Lymph Node Dissection for Female Patients with T3-4c Breast Cancer.
Li P; Yang C; Zhang J; Chen Y; Zhang X; Liang M; Huang N; Chen Y; Wang K
Oncologist; 2023 Aug; 28(8):e591-e599. PubMed ID: 36929946
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
11. Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis.
Chung SH; de Geus SWL; Shewmaker G; Romatoski KS; Drake FT; Ko NY; Merrill AL; Hirsch AE; Tseng JF; Sachs TE; Cassidy MR
Ann Surg Oncol; 2023 Sep; 30(9):5610-5618. PubMed ID: 37204557
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
13. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
[TBL] [Abstract][Full Text] [Related]
15. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Fu Y; Chung D; Cao MA; Apple S; Chang H
Ann Surg Oncol; 2014 Dec; 21(13):4109-23. PubMed ID: 25081336
[TBL] [Abstract][Full Text] [Related]
16. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
[TBL] [Abstract][Full Text] [Related]
17. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
Yi M; Giordano SH; Meric-Bernstam F; Mittendorf EA; Kuerer HM; Hwang RF; Bedrosian I; Rourke L; Hunt KK
Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):343-51. PubMed ID: 20853057
[TBL] [Abstract][Full Text] [Related]
18. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
19. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
Zheng Q; Luo H; Xia W; Lu Q; Jiang K; Hong R; Xu F; Wang S
Breast Cancer Res Treat; 2022 Dec; 196(3):613-622. PubMed ID: 36207619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
